Johnson and Johnson Pharmaceutical Research and Development

NCT07308132

Phase 1Recruiting340 people29 Dec 2025clinicaltrials.gov

NCT07276399

Phase 3Recruiting500 people11 Dec 2025clinicaltrials.gov

NCT07032714

CollaboratorPhase 1Recruiting25 people24 Jun 2025clinicaltrials.gov

NCT06577025

Phase 2Active, not recruiting43 people29 Aug 2024clinicaltrials.gov

NCT06348108

CollaboratorPhase 1Recruiting32 people4 Apr 2024clinicaltrials.gov

NCT06208150

Phase 3Active, not recruiting838 people17 Jan 2024clinicaltrials.gov

NCT06120140

Phase 2Active, not recruiting305 people7 Nov 2023clinicaltrials.gov

NCT05695508

CollaboratorPhase 2Recruiting160 people25 Jan 2023clinicaltrials.gov

NCT05674656

CollaboratorPhase 1/2Recruiting20 people6 Jan 2023clinicaltrials.gov

NCT05663866

Phase 2Active, not recruiting68 people23 Dec 2022clinicaltrials.gov

NCT05572515

Phase 3Active, not recruiting614 people7 Oct 2022clinicaltrials.gov

NCT05552222

Phase 3Recruiting1,590 people23 Sept 2022clinicaltrials.gov

NCT05521087

Phase 1Withdrawn0 people30 Aug 2022clinicaltrials.gov

NCT05469893

CollaboratorPhase 2Recruiting52 people22 Jul 2022clinicaltrials.gov

NCT05455320

Phase 3Active, not recruiting864 people13 Jul 2022clinicaltrials.gov

NCT05438043

Phase 3Active, not recruiting213 people29 Jun 2022clinicaltrials.gov

NCT05257083

CollaboratorPhase 3Active, not recruiting759 people25 Feb 2022clinicaltrials.gov

NCT05250973

Phase 2Active, not recruiting151 people22 Feb 2022clinicaltrials.gov

NCT05083169

Phase 3Active, not recruiting587 people19 Oct 2021clinicaltrials.gov

NCT05076877

Phase 1Completed20 people13 Oct 2021clinicaltrials.gov

APOE and amyloid-tau pathology in cognitively unimpaired older adults

1 Jul 2026api.crossref.org